Novo Holdings led a $100m Series C round in SiteOne Therapeutics.

Novo Holdings, an investment company, led a $100m Series C round in SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, with participation from OrbiMed, Wellington Management, Mission BioCapital, BSQUARED Capital. “SiteOne Therapeutics’ portfolio of selective ion channel modulators holds immense promise for the non-opioid treatment of pain. SiteOne has built upon years of research on the contribution of ion channels to peripheral nerve excitability, and we are very encouraged by the company’s underlying science and its mission to transform pain management for patients living with chronic pain in the US and around the globe,” Ken Harrison, Novo Holdings Senior Partner.